cisplatin + S-1

HIPEC-Tang-Du Hospital-gastric cancer refers to a specific therapeutic regimen evaluated in a Phase 3 clinical trial (NCT02396498) led by Tang-Du Hospital. The treatment consists of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin in combination with oral S-1 for patients with stage III gastric cancer following D2 radical gastrectomy. Cisplatin is a platinum-based small molecule that functions as a DNA alkylating agent, creating crosslinks that interfere with DNA replication and transcription, ultimately triggering apoptosis. S-1 is a composite oral fluoropyrimidine consisting of tegafur (a 5-FU prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor). This combination is designed to maximize the anti-tumor activity of 5-fluorouracil while minimizing systemic and gastrointestinal toxicity. The regimen specifically targets residual micrometastases within the peritoneal cavity to improve survival outcomes in advanced gastric cancer patients.

Other names

S-1 plus cisplatin HIPECS1 plus cisplatin HIPECS 1 plus cisplatin HIPECHIPEC-Tang-Du Hospital-gastric canceradjuvant HIPEC with cisplatin and S-1